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ABSTRACT 
A novel Propafenone HCl gastric-resident tablet was developed. A controlled release matrix tablet was prepared by 
using various controlled release polymers i.e. HPMC E5 and HPMC K100M. Pharmaceutical zinc oxide powder 
was used as a density-increasing agent. The formulations were evaluated for pharmacopoeial quality control tests 
and all the physical parameters evaluated were within the acceptable limits. Prepared high density tablet showed 
density up to 1.63 gm/cm3 which is higher than the gastric fluid. Also it shows good dimensional stability till the 12 
h. In vitro release study shows the good drug release up to the 12 h. Stability studies were carried out on the 
optimized formulation for period of 3 months at 400c / 75%RH. Finally it was observed that there was no change in 
physiochemical and physical properties as well as in drug release profile even after storage at 45 °C and 75 % for 
three months. Zinc oxide increases the system density, making the system resident in stomach to prolong the drug 
delivery time in absorption zone. 
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INTRODUCTION 
Oral controlled release drug delivery system has overcome every one of the disadvantages of conventional drug 
delivery system and for this reason is the mainly ideal route. However, due to a number of physiological difficulties, 
such as an incapability to restrain and localize the drug delivery system in preferred regions of the GIT and the very 
much changeable nature of gastric emptying process, predictable and increased bioavailability of drugs cannot be 
achieved. 1-4 
A variety of systems such as mucoadhesive, swelling, floating system and high density, have been developed to 
enhance GRT of a dosage form. Physiological features of the upper gastrointestinal tract shows significant challenge 
to develop such systems. However, in vivo studies of some systems shown promising results. High-density systems 
are proposed to lodge in the rugae of the stomach withstand the peristaltic activities. Dosage form with a density of 
1.3 g/ml or higher are likely to be retained in the lower part of the stomach. 
The formulation of heavy pellets is based on the hypothesis that the pellets might be located in the lower part of the 
antrum because of their higher density shown in Figure 1. Clarke et al. reported that the critical density to delay 
gastric residence of pellets ranges between 2.4 to 2.8 g/ml. Though, in vivo data do not proved the efficiency of this 
system, as the most important determining factor of gastric emptying is the state of stomach when it is administered. 
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Devreux et al reported that the pellets have density of at least 1.5 g/ml have considerably higher GRT both in fed 
and fasted state. 
 
Figure 1: (a) High density system. (b) Low density system. 
(c) Mucoadhesive systems. 
Propafenone HCl is one of the antiarrhythmic agents, which is a Class 1C antiarrhythmic drug with local anesthetic 
effects, and direct stabilizing action on myocardial membranes. It has less half-life of about 2-10 hours and oral 
bioavailability very less, i.e. 10 %. Due to this reason it has to be taken frequently, i.e. 150 mg 3 times a day or 300 
mg twice a day. To increase the bioavailability of Propafenone, gastroretentive drug delivery system was selected in 
which the dosage form is retained in the stomach so that it can be released for an extended period of time. 
The drugs should have following properties to be the ideal candidates for gastroretention, a) narrow absorption 
window b) less bioavailability c) less plasma half life  
Propafenone HCl an antiarrhythmic agent has a narrow absorption window i.e. it is erratically absorbed through 
GIT, less bioavailability of about 10 % and hence requires frequent dosing. It also has less plasma half-life. Drugs 
having pH dependent solubility i.e. highly soluble at low pH (gastric pH) and poorly soluble at high pH (intestinal 
pH) are the suitable drug candidates for the gastroretentive drug delivery system. In the treatment of angina, 
hypertension, cardiac arrhythmias, a loading as well as maintenance dose is required. Thus, Propafenone HCl has all 
the properties required for gastroretention and hence it was selected as the candidate drug for gastroretentive drug 
delivery system. 5-7 
MATERIAL AND METHODS 
Material 
Propafenone Hydrochloride as reference substances were supplied by Glenmark Pharmaceuticals Ltd., Mumbai. 
HPMC E5, HPMC K100M, Zinc oxide, Magnesium stearate, Lactose and isopropyl alcohol were purchased from 
Loba Chemie Pvt. Ltd. Mumbai. PVP K-30 was purchased from Signet Chemical Corporation, Mumbai.  
Methods 
 Preparation of high density Propafenone HCl tablet 
The granules were prepared by wet granulation method as per formulae given in the above Table (twenty tablets for 
each formulation). The drug Propafenone Hydrochloride, hydrophilic polymer (HPMC K100M, HPMC E5), Zinc 
oxide, were passed through sieve 40# separately and blended thoroughly. After proper mixing then slowly add the 
binding solution containing PVP K-30 in IPA (Iso propyl alcohol) till fine uniform granules were obtained. The wet 
mass was passed through sieve 16# and dried at 50 °C for 30 minutes to get the moisture content less than one. Then 
lubricate the dried granules with magnesium stearate which were already passed through sieve 40#. Then lubricated 
granules were compressed on cadmach tablet punch machine for all formulations.8 The formulations containing 
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Table 1: Composition of gastroretentive high density Tablet (quantities in mg) 
Formulation code H1 H2 H3 H4 H5 H6 H7 H8 
Propafenone 
Hydrochloride 
300 300 300 300 300 300 300 300 
HPMC E5 100 150 200 - - - 150 100 
HPMC K100M - - - 100 150 200 100 150 
Zinc oxide 35 35 35 35 35 35 35 35 
PVP K30 20 20 20 20 20 20 20 20 
Magnesium Stearate 10 10 10 10 10 10 10 10 
Lactose 235 185 135 235 185 135 85 85 
 
Table 2: Composition of gastroretentive high density Tablet (quantities in mg) 
Formulation code H9 H10 H11 H12 H13 H14 H15 H16 
Propafenone 
Hydrochloride 
300 300 300 300 300 300 300 300 
HPMC E5 100 100 150 150 100 150 100 150 
HPMC K100M 200 100 150 150 100 100 150 150 
Zinc oxide 35 35 35 40 50 50 50 50 
PVP K30 20 20 20 20 20 20 20 20 
Magnesium Stearate 10 10 10 10 10 10 10 10 
Lactose 35 135 35 30 120 70 70 20 
 
Evaluation of granules 
Angle of repose 
Granules flowability was determined by calculating angle of repose by funnel technique. A funnel with 10 mm inner 
diameter of stem was fixed at a height of 2 cm above the platform. About 20 g of granules was slowly passed along 
the wall of funnel till the tip of the pile produced and touches the stem of the funnel. A rough circle was drawn about 






 ?  = angle of repose 
  h = height of the pile 
  r = average radius of the powder cone. 
Bulk Density 
Apparent bulk density of granules was determined by the graduated cylinder and measuring the volume and weight 
“as it is”.10 Bulk density was calculated by using following formula:  
                                            Weight of sample in grams 
Bulk density (g/mL) =    
                                       Volume occupied by the sample 
Tapped Density 
Tapped density was determined with the aid of tapped density tester apparatus. In this method 20 gm of sample was 
poured gently through a glass funnel in to a 100mL graduated cylinder. The cylinder was then placed in the 
apparatus and parameters were set to carry out the test.10 Volume occupied by the sample after tapping were 
recorded and tapped density was calculated by following formula:                                
                                                    Weight of sample in grams 
Tapped density (g/mL) =         
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                                          After tapping volume occupied by the sample  
Hausner ratio 
It provides an indication of the degree of densification which could result from vibration of the feed hopper. Hausner 
ratio closer of less than 1.25 indicates good flow, while greater than 1.5 indicates poor flow materials.11 
                                Tapped density 
Hausner ratio =       
                                                       Bulk density 
Carr’s index or % compressibility 
Carr’s index or % compressibility11 was calculated by using following equations: 
                                    Tapped density - Bulk density 
           Carr’s index = × 100 
Evaluation of high density tablets  
Tablet thickness and diameter 
Tablet Thickness and diameter were accurately measured by using digital vernier caliper in mm. 12 Results were 
expressed as mean values ± SD. 
 
 
Hardness and Friability 
Hardness of tablet was determined by Monsanto hardness tester. Friability test was done by Roche friabilator. Ten 
tablets were weighed and were subjected to the combined effect of attrition and shock by utilizing a plastic chamber 
that revolve at 25 rpm dropping the tablets at distance of 6 in. with each revolution. Operated for 100 revolutions, 
the tablets were de dusted and reweighed.13 The percentage friability was calculated. 
                                         W1 ?W2 
                               F =   × 100 
                                             W1 
Where F represents the percentage weight loss, and W1 and W2 are the initial and final tablet weights, respectively. 
Weight variation 
Twenty tablets were selected at random and average weight was determined. Then individual tablets were compared 
with the average weight.13 
Tablet density 
The density (D) of tablets was calculated from tablet thickness, diameter, and weight by using the following 
equation: 
 
                                              w 
                         D =     
                                       (m/2)2 × ? × h 
Here, m is the diameter of a tablet, ? is the circular constant, h is the thickness of a tablet, and w is the weight of a 
tablet.14 All measurements were performed in three replicates. The averages and standard deviations were calculated 
and reported. 
Drug content 
For determination of drug content, Weighed and powder 5 tablets, then weighed accurately a quantity of the powder 
equivalent to about 100 mg of Propafenone HCl, transfer to a 100ml volumetric flask and dissolved in 100 ml of 
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Dimensional stability 
The dimensional stability of the formulations was studied by using USP dissolution Apparatus II. The dissolution 
medium was 0.1N HCL and the volume being 900mL, the temperature was maintained at 37 °C. The rotation speed 
was 100 rpm. The dimensional stability of gastroretentive high density tablet was observed visually.16 
Drug release study 
Three tablets of each formulation were used in the release experiment. The release rates of Propafenone HCl were 
determined using USP apparatus I (basket apparatus) at 37 °C in 900 ml of 0.1N HCl solution (pH, 1.2) with the 
rotation speed of 100 rpm. At appropriate time intervals 0.25. 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h, 5ml of sample was 
withdrawn and an equal volume of medium was added to keep the volume constant. Samples were analyzed 
spectrophotometrically at 301 nm.16 
Accelerated stability study of optimized formulations 
Accelerated stability study was carried out for optimized formulations, to assess its stability as per ICH guidelines. 
The optimized formulation were wrapped in the laminated aluminum foils and was placed in the accelerated stability 
chamber (6CHM-GMP, Remi Instrument Ltd., Mumbai) at elevated temperature and humidity conditions of 400C/ 
75% RH and a control sample was placed at an ambient condition for a period of three months. Sampling was done 
at a predetermined time of initial 0, 1, 2 and 3 months interval respectively. At the end of study, samples were 
analyzed for the drug content, in vitro drug release profile and other physicochemical parameters.17-19 
RESULT AND DISCUSSION 
Granules evaluation 
The physical characteristics of the granules (H1 to H16) such as bulk density, tapped density, carr's index, husners 
ratio, angle of repose were determined. The results are given in Table 3. The bulk densities were ranged from 0.963-
1.060 gm/ml. The tapped densities were ranged from 1.104-1.220 gm/ml. The carr's compressibility index were 
ranged from 10.77-20.61%. The housners rations were found to be in the limit 1.12-1.25. The angles of repose of all 
formulation were found to be between the limit 22.19°-26.61°. All the formulation shows excellent flow properties. 
So, the granule passes the evaluated tests and subjected to next stage of work compression. 
Table 3: Evaluation and characterization of granules 
Formulation code 










Angle of repose 
x 
( ° ) 
H1 0.970±0.05 1.131±0.02 14.23±0.19 1.17±0.06 23.68±0.99 
H2 0.966±0.07 1.124±0.01 14.05±0.11 1.16±0.03 23.30±2.04 
H3 0.971±0.02 1.115±0.04 12.91±0.13 1.14±0.05 25.15±2.65 
H4 1.060±0.01 1.220±0.03 13.11±0.10 1.15±0.03 24.68±2.17 
H5 0.976±0.05 1.185±0.04 17.63±0.21 1.23±0.02 26.39±1.49 
H6 0.963±0.06 1.185±0.04 18.73±0.26 1.24±0.04 23.16±1.38 
H7 0.985±0.07 1.104±0.02 10.77±0.15 1.12±0.04 22.19±2.76 
H8 0.981±0.03 1.111±0.01 11.70±0.09 1.13±0.03 26.61±2.09 
H9 0.909±0.02 1.145±0.06 20.61±0.18 1.25±0.01 25.43±2.44 
H10 0.981±0.06 1.117±0.03 12.17±0.08 1.13±0.07 22.61±2.27 
H11 0.985±0.03 1.146±0.04 14.04±0.09 1.16±0.03 23.68±1.97 
H12 0.978±0.06 1.115±0.02 12.28±0.09 1.14±0.07 25.72±1.44 
H13 0.988±0.01 1.136±0.02 13.02±0.06 1.15±0.02 24.14±2.89 
H14 0.969±0.04 1.116±0.05 13.17±0.10 1.15±0.08 23.71±2.68 
H15 0.973±0.06 1.113±0.01 12.57±0.11 1.14±0.06 24.05±2.63 
H16 0.983±0.02 1.121±0.03 12.31±0.15 1.14±0.09 23.18±2.79 
x= mean; ± SD; n= 3 
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Tablet thickness and diameter 
The thickness of the tablets range from 3.24-3.98 mm respectively. The diameter of the tablet in the range of 12.95-
13.01mm.There is no variation in tablet thickness and diameter between the formulations. The results are given in 
Table 4. 
Hardness, friability and weight uniformity of tablets 
The hardness of the tablet were within the range and optimum for controlled release, and ranging from 7.4-8.2 
Kg/cm2 for all H1-H16 formulations. The friability of all formulations was ranging from 0.084-0.219 % w/w and 
passes as per IP limit should not be more than 1 % w/w. The weight uniformity of tablet in all formulation was 
observed to be within the IP limit 10 %. All formulations were complying with the official test. The values were 
mentioned in Table 4. 
Table 4: Evaluation of Propafenone HCl high density tablet 
Formulation Thickness
 x  
mm 
Diameter x  mm Hardness
 x  
Kg/cm2 





H1 3.98±0.02 13.00±0.03 7.6±0.11 0.120±0.02 699.04±2.14 
H2 3.86±0.03 13.01±0.04 7.4±0.09 0.138±0.05 705.41±1.91 
H3 3.75±0.02 12.99±0.03 7.7±0.08 0.098±0.01 703.43±1.66 
H4 3.81±0.01 12.98±0.02 7.5±0.15 0.219±0.06 695.78±1.43 
H5 3.61±0.03 12.98±0.03 7.9±0.10 0.154±0.03 703.65±2.74 
H6 3.58±0.03 13.01±0.01 7.5±0.09 0.135±0.02 698.09±2.37 
H7 3.67±0.01 13.01±0.02 8.0±0.03 0.103±0.03 695.56±2.81 
H8 3.60±0.03 12.98±0.02 7.8±0.16 0.189±0.07 697.90±2.90 
H9 3.61±0.02 12.95±0.03 7.4±0.06 0.141±0.10 704.58±3.01 
H10 3.74±0.02 13.01±0.03 7.9±0.10 0.084±0.09 706.32±1.16 
H11 3.53±0.03 12.98±0.03 7.8±0.13 0.093±0.13 707.13±1.08 
H12 3.39±0.01 12.99±0.01 7.9±0.05 0.128±0.12 698.61±1.78 
H13 3.32±0.01 12.98±0.02 8.1±0.12 0.138±0.09 706.13±2.35 
H14 3.29±0.01 12.98±0.02 8.2±0.09 0.098±0.11 701.18±2.38 
H15 3.24±0.03 12.99±0.02 8.0±0.18 0.104±0.14 698.88±3.82 
H16 3.24±0.02 12.98±0.03 7.9±0.06 0.219±0.12 696.93±1.68 
x= mean; ± SD; n= 3 
Tablet density 
The tablet densities of all the formulation were in the range of 1.32-1.63 gm/cm3,  which  was  the  greater  than  the  
gastric fluid and optimum for the gastroretentive high density system. 
Drug content  
The assays of all formulation from H1-H16 were found to be between 99.19-99.71 %. The result shows that all 
formulation containing drug were within the limit (99-101 %). 
Dimensional Stability 
It is important to maintain the physical integrity of the tablet up to 12 h in case of once daily formulations. In all 
formulations the concentrations of polymers also act as release retardant was increased in ascending order to achieve 
the in vitro release. So increasing concentrations the dimensional integrity of tablet also increased respectively. The 
dimensional integrity of formulations was represented with code (+++) excellent, (++) very good, (+) good, (-) lack 
of integrity, along with picture representation in Table 5 and Figure 2. 
The formulation H2-H16 shows excellent dimensional stability, except formulation H1 shows the good dimensional 
stability. 
                        ( +++ )                                                  ( ++ ) 
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                         ( + )                                                          ( - )  
                    
Figure 2: Picture representation coding for dimentional stability 
 
 
Table 5: Tablet density and drug content of Propafenone HCl high density tablet 
Formulation Tablet density x 
(gm/cm3) 




H1 1.32±0.02 99.31±0.21 ++ 
H2 1.37±0.01 99.39±0.15 +++ 
H3 1.41±0.03 99.49±0.09 +++ 
H4 1.38±0.02 99.20±0.18 +++ 
H5 1.47±0.02 99.27±0.12 +++ 
H6 1.46±0.03 99.59±0.19 +++ 
H7 1.42±0.01 99.24±0.05 +++ 
H8 1.46±0.01 99.56±0.11 +++ 
H9 1.48±0.01 99.39±0.14 +++ 
H10 1.42±0.02 99.19±0.06 +++ 
H11 1.51±0.04 99.52±0.09 +++ 
H12 1.55±0.02 99.37±0.13 +++ 
H13 1.60±0.03 99.43±0.11 +++ 
H14 1.61±0.01 99.62±0.06 +++ 
H15 1.63±0.02 99.71±0.28 +++ 
H16 1.63±0.02 99.25±0.07 +++ 
                x= mean; ± SD; n= 3 
In vitro drug release study 
In our work, we have shown the effect of polymers on in vitro drug release studies of Propafenone HCl. Formulation 
batch H1-H6 releases drug in 6-8 h due to single use of polymer. In the later batches H7-H16 use of combination of 
polymers in that case it exhibits good drug release up to the 12 h. Formulation H15 shows maximum drug release 
94.10% with controlled manner showed in Table 6 and 7. 
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Table 6: Cumulative % drug release of formulated high density tablet 
Time 
(h) 
Cumulative % drug release x 
H1 H2 H3 H4 H5 H6 H7 H8 
0.25 7.31± 0.58 6.84±0.61 6.61±0.09 6.53±0.85 5.38±1.01 5.51±0.91 5.05±0.69 3.43±0.44 
0.5 12.38±0.91 11.74±1.73 8.58±0.98 9.27±1.03 9.40±1.68 7.73±1.13 8.43±1.26 7.14±0.96 
1 21.85±1.68 17.58±2.37 16.66±1.55 15.72±2.16 14.43±1.97 10.41±1.65 9.71±1.75 11.53±1.51 
2 37.73±2.43 32.67±3.55 28.04±2.31 29.90±2.73 23.74±2.13 19.73±2.38 17.49±2.01 19.47±2.84 
3 49.92±3.58 42.92±3.06 38.16±3.76 41.58±2.94 31.48±2.47 27.51±3.29 30.78±2.90 25.73±2.93 
4 64.17±3.96 53.84±4.17 46.43±3.43 49.38±3.25 41.79±2.61 38.33±2.77 43.82±3.83 35.07±3.07 
6 89.62±3.68 76.37±3.89 61.79±3.13 64.66±4.78 56.28±2.84 52.71±3.08 60.75±3.85 52.89±3.81 
8 - 84.76±3.52 88.65±3.79 89.39±4.47 69.31±3.98 61.02±3.51 73.44±3.89 69.30±3.47 
10 - - - - 90.33±2.83 84.88±4.72 81.86±2.15 83.44±3.26 
12 - - - - - - 91.85±1.42 92.41±1.04 
x= mean; ± SD; n= 3 
Table 7: Cumulative % drug release of formulated high density tablet 
Time 
(h) 
Cumulative % drug release x 
H9 H10 H11 H12 H13 H14 H15 H16 
0.25 3.34±0.25 3.98±0.37 4.01±0.41 6.83±0.09 8.78±1.19 7.16±1.21 7.03±0.95 4.53±0.08 
0.5 5.15±0.88 7.49±0.84 8.52±0.62 9.41±1.18 13.73±1.82 10.52±1.38 9.19±1.38 7.24±0.83 
1 9.43±1.17 12.78±1.36 13.81±1.80 16.98±2.74 23.79±2.35 19.44±1.43 15.42±1.41 13.75±1.40 
2 16.73±1.97 19.44±2.49 19.44±1.66 26.43±2.17 37.11±2.74 28.87±2.58 25.71±2.58 22.14±1.58 
3 23.43±2.43 27.67±3.85 26.48±2.38 38.18±3.03 48.54±2.96 33.74±3.61 33.86±2.77 29.65±1.53 
4 31.69±2.83 34.44±3.83 32.65±2.61 49.55±3.73 55.68±3.73 46.61±4.79 42.27±3.96 39.81±3.45 
6 43.90±2.47 53.78±3.51 51.74±3.05 62.14±3.65 73.62±3.25 67.35±4.48 58.38±3.86 53.48±3.82 
8 53.17±3.33 76.64±4.62 67.95±3.69 70.46±3.31 83.46±3.38 78.35±4.81 76.84±3.73 70.34±3.91 
10 69.64±3.85 93.98±3.85 82.63±3.27 81.28±3.09 92.78±2.41 86.25±3.64 85.49±2.07 81.37±3.27 
12 85.43±2.63 - 89.68±0.14 85.21±1.67 - 90.36±2.06 94.10±1.16 90.18±2.77 
x= mean; ± SD; n= 3 
Accelerated stability study 
Propafenone HCl optimized formulation was found to be stable during accelerated stability studies for drug content 
99.71, 99.61, 99.48 and 99.36% at 0, 1, 2 and 3 months respectively at 400c/75% RH. In vitro drug release studied 
for 12 h was found to be 94.10, 93.68, 91.73 and 91.08% at 0, 1, 2 and 3 months respectively at 400c / 75%RH. 
Tablet density of optimized formulation was found to be 1.63, 1.63, 1.62 and 1.62 gm/cm3 at 0, 1, 2 and 3 months 
respectively at 400c  /  75%RH.  Results  obtained  are  shown  in  Table  8.  Finally  it  was  observed  that  there  was  no  
change in physiochemical and physical properties as well as in drug release profile even after storage at 45 °C and 
75 % for three months. It  may be inferred that there was no degradation of physical properties and change in the 
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Table 8: Results of Accelerated stability study of optimized formulations 
  
Optimized formulation 
   Drug content  
          (%) 
% drug release 
Tablet density 
(gm/cm3) 
Initial 99.71 94.10 1.63 
One month 
Ambient 99.65 93.73 1.63 
400c / 75%RH 99.61 93.68 1.63 
Two month 
Ambient 99.56 92.18 1.63 
400c / 75%RH 99.48 91.73 1.62 
Three month 
Ambient 99.49 91.58 1.63 
400c / 75%RH 99.36 91.08 1.62 
 
CONCLUSION 
The present study concludes that the Propafenone HCl high density tablet pH could be successful option for the 
gastroretentive drug delivery system for cardiac arrhythmias. Loading and maintenance dose was maintained with 
the proper selection of controlled release polymers such as, HPMC E5 and HPMC K100M. Zinc oxide highly 
increases density of the tablet. Thus, the designed formulation can be considered as one of the promising 
formulation techniques for preparing Propafenone HCl high density tablet for the gastroretentive drug delivery 
system in management of cardiac arrhythmias and other diseases. 
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